Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2025; 16(9): 110639
Published online Sep 15, 2025. doi: 10.4239/wjd.v16.i9.110639
Published online Sep 15, 2025. doi: 10.4239/wjd.v16.i9.110639
Trends in baseline blood lipid levels in randomized placebo-controlled trials of overweight or obesity from 1990 to 2024
Ya-Qi Wang, Yan Yang, Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha 410000, Hunan Province, China
Quan-Zhou Xiao, Department of Spine Surgery, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
Zhen-Ming Zhang, Department of Pulmonary and Critical Care Medicine, People’s Hospital of Ningxiang City, Changsha 410011, Hunan Province, China
Co-corresponding authors: Zhen-Ming Zhang and Yan Yang.
Author contributions: Wang YQ and Yang Y were involved in the design and manuscript drafting; Wang YQ, Xiao QZ, and Zhang ZM handled the study selection, data extraction, quality assessment, and data analysis; Zhang ZM and Yang Y conducted supervision and settled disputes, and they contribute equally to this study as co-corresponding authors.
Conflict-of-interest statement: The authors declare that they have no current competing interests.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Yang, Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Changsha 410000, Hunan Province, China. 228201015@csu.edu.cn
Received: June 11, 2025
Revised: July 23, 2025
Accepted: August 27, 2025
Published online: September 15, 2025
Processing time: 92 Days and 17.4 Hours
Revised: July 23, 2025
Accepted: August 27, 2025
Published online: September 15, 2025
Processing time: 92 Days and 17.4 Hours
Core Tip
Core Tip: This global meta-analysis of 866 randomized trials (n = 3300) reveals significant improvements in lipid profiles among overweight/obese individuals over three decades, with triglycerides, total cholesterol and low-density lipoprotein-cholesterol declining while high-density lipoprotein-cholesterol increased. Notably, pharmacological interventions showed the most pronounced benefits. These findings highlight that despite rising obesity rates, concerted public health efforts and therapeutic advances have successfully mitigated dyslipidemia risks in this high-risk population, offering crucial insights for clinical practice and health policy.